What is CTOR's market cap?

$57.85M, based on the Nov 4 close of $0.55.

Does Citius Oncology pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CTOR is sold short?

227.5K shares, 0.8% of float, as of Oct 15, 2026.

What sector is CTOR in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · CTORHealthcarePharmaceuticals

Citius Oncology, Inc. Common Stock (CTOR)

$0.5470−0.55%

Close Nov 4, 2026 · split-adjusted

Oct 30, 2026$0.55▼ 68.34% in range

Oct 31, 2025Low $0.49 · High $1.75Oct 30, 2026

What changed · written from our data

As of Nov 4, 2026

Citius Oncology closed at $0.55 on Nov 4, down 0.55%, 67.2% below its 52-week closing high. Volume of 80.1K shares was 0.55× its 20-day average (below normal).

Split-adjusted performance: -35.6% over one month, -39.8% over six months, -67.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.49M, with a net margin of -597.4%.

Short interest was 227.5K shares at the Oct 15 settlement, down 21.5% from the prior report (0.8% of float, 2.7 days to cover).

Market cap$57.9M105.8M shares

Revenue · quarter$1.5M—

Diluted EPS$-0.08—

P/E · TTM—P/S 8.1×

Net margin-597.4%Gross 67.1%

Dividend yieldNone

52-week range0.49 – 1.67−67.2% from high

Volume80.1K0.55× 20-day avg

Volatility · 60d98.9%Annualised

Short % of float0.8%2.7 days to cover

Net cash$10.2MCash $16.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.2%1M −35.6%3M −28.0%6M −39.8%YTD −45.3%1Y −67.2%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum34

Revenue growth—

Net margin28

Value (low P/E)—

Size33

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short227.5K−21.5% vs prior

Days to cover2.7Settled Oct 15

% of float0.8%

Short vol. 10d24.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CTORCitius Oncology	$0.5470	−0.55%	−39.8%	—	−597.4%	—	$57.9M
NMADNomad Power Solutions	$3.60	+2.27%	—	—	—	—	$58.0M	Compare
CLNNClene	$4.10	+8.75%	−42.7%	+233.3%	−14915.6%	—	$58.3M	Compare
XLOXilio Therapeutics	$8.71	+0.35%	+10.3%	+131.2%	−34.1%	—	$57.3M	Compare
RNTXRein Therapeutics	$0.6587	−1.32%	−43.7%	—	—	—	$56.8M	Compare
HRTXHeron Therapeutics	$0.2986	+4.88%	−77.2%	+1.3%	−14.6%	—	$56.7M	Compare
RNXTRenovoRx	$1.31	+1.55%	+47.2%	+115.4%	−320.2%	—	$59.1M	Compare
VRCAVerrica Pharmaceuticals	$3.46	+5.02%	−59.0%	−53.8%	−224.4%	—	$59.4M	Compare
XBITXBiotech	$1.95	−2.01%	−23.5%	—	—	—	$59.5M	Compare

News about Citius Oncology

All news →

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Benzinga · Feb 13, 2026▲ Positive Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Benzinga · Feb 13, 2026▲ Positive

Quick answers

What does Citius Oncology do?: Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.
What is CTOR's market cap?: $57.85M, based on the Nov 4 close of $0.55.
Does Citius Oncology pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CTOR is sold short?: 227.5K shares, 0.8% of float, as of Oct 15, 2026.
What sector is CTOR in?: Healthcare, in the Pharmaceuticals industry.

About Citius Oncology

Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.

HQ: Cranford, NJListed Aug 13, 2024citiusonc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology